Coronary Stent Restenosis in Patients Treated With Cilostazol

Abstract

Background-Restenosis after implantation of coronary artery stents remains a significant clinical problem. We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries. Methods and Results-We assigned 705 patients who had successful coronary stent implantation to receive, in addition to aspirin, cilostazol 100 mg BID or placebo for 6 months; clopidogrel 75 mg daily was administered to all patients for 30 days. Restenosis was determined by quantitative coronary angiography at 6 months. The minimal luminal diameter at 6 months for cilostazol-treated patients was

Effect of Cilostazol in Preventing Restenosis after Carotid Artery Stenting Using the Carotid Wallstent: A Multicenter Retrospective Study

“…Douglas et al 14 reported a randomized double-blind placebocontrolled trial in 705 subjects after coronary artery stent placement; there was significantly inhibited restenosis in the CLZ group, with a restenosis rate of 22.0% in the CLZ group and a restenosis rate of 34.5% in the placebo group. Iida et al 15 reported that in a prospective randomized study on vasodilation and stent placement procedures for femoropopliteal lesions (characterized by high rates of restenosis), a comparison of 63 lesions treated with aspirin and CLZ and 64 lesions treated with aspirin and ticlopidine showed that the patency rates after 1, 2, and 3 years were 87%, 82%, and 73%, respec-tively, in the CLZ group, and 65%, 60%, and 51%, respectively, in the ticlopidine group, with significant inhibition of restenosis by CLZ.…”

Cilostazol Prevents Progression of Asymptomatic Carotid Artery Stenosis in Patients with Contralateral Carotid Artery Stenting

“…Several recent studies reported that cilostazol reduced restenosis and repeat revascularization after coronary intervention with either a bare-metal stent or a drug-eluting stent. 20,22,26,49,50 Similarly, cilostazol reduced restenosis after endovascular therapy in peripheral arteries, [15][16][17][18] and some studies reported the effectiveness of cilostazol in the prevention of restenosis after CAS. In 1 study, restenosis during a 29-month period after CAS occurred in none (0/ 27) of the patients who received cilostazol and in 15.7% (11/70) of patients who did not receive cilostazol.…”

“…14 In patients with coronary and peripheral artery disease, cilostazol has been shown to decrease restenosis and revascularization after catheter intervention. [15][16][17][18][19][20][21][22][23][24][25][26] Furthermore, some previous reports suggested that cilostazol reduced restenosis after CEA and CAS.…”

Impact of Chronotropic Effect of Cilostazol After Acute Myocardial Infarction Insights From Change in Left Ventricular Volume and Function

“…[13][14][15][16] Cilostazol selectively inhibits cyclic adenosine monophosphate-selective phosphodiesterase, increasing the intracellular level of cyclic adenosine monophosphate. As would be expected, it may increase HR, myocardial contractility, and ventricular automaticity.…”